NEW YORK (360Dx) – Saladax Biomedical said today that it has inked a non-exclusive agreement to license two Alzheimer's diagnostic tests to Siemens Healthineers.

The tests identify the amyloid beta 1-42 and tau biomarkers, two indicators of the early stages of Alzheimer's disease, in cerebrospinal fluid.

Saladax said that under the agreement, it will provide its "proprietary" raw materials, protocols, and intellectual property, and Siemens will commercialize both assays.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Sponsored by
Thermo Fisher Scientific

This webinar will discuss how ultra-highly sensitive and customizable targeted next-generation sequencing panels are applied in inherited disease research. 

Sponsored by

This online seminar will discuss the advantages of incorporating molecular testing into the microbiology laboratory to aid in the identification of relevant antibiotic resistance mechanisms.